Adding Darolutamide: New SOC for Metastatic Prostate Cancer Adding Darolutamide: New SOC for Metastatic Prostate Cancer

Darolutamide added onto ADT and docetaxel could be a new standard of care for men with metastatic hormone-sensitive prostate cancer.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news